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Alternative Artificial Vein Graft Biomaterials 
Alexander J. Whitehead 
 
Abstract 
 Current artificial vein grafts for long-term dialysis and 
bypass surgeries suffer from atherosclerosis and restenosis, and 
they tend to thrombose after initial patient recovery. The 
alternative materials, coatings, and polymer interfaces being 
explored in stents may be useful in graft applications, increasing 
both the quantity and quality of the patient’s life. To better 
comprehend the clinical standards and developing alternatives, I 
collected previously identified physical and chemical venous 
properties, as well as the corresponding synthetic materials that 
would support them. I compiled studies of primary and 
secondary endpoints (such as death, myocardial infarction, 
thrombosis, and target-lesion revascularization) in various graft 
materials, polymer coatings, and drugs to gauge efficacy. Based 
on my findings, I suggest that everolimus coatings linked to 
polytetrafluoroethylene (PTFE) grafts by poly(n-butyl 
methcrylate) (PBM) should be subjected to further clinical 
research and in-vivo trials.  
Introduction 
Modern artificial graft options evolved over time from much 
simpler designs. The first attempts at artificial vein grafts began 
in the 1930s with Dupont, who created a thin-walled, carbon 
coated and pre-cuffed graft made out of polytetrafluoroethylene 
(PTFE)[1]. It was made in a ringed configuration with a porous 
structure. It essentially looked like a small plastic tube. In 1950, 
DuPont manufactured a polyethylene terephthalate vascular 
implant that had to be pre-clotted. The fabric was woven, and it 
used collagen or albumin, which are used today. Gortex was 
also developed, which contained heparin that lasted for more 
than 230 days in vivo. Later, in 2004, this was proven by Dr. P. 
Lin in the Journal of Vascular Surgery to reduce neointimal 
hyperplasia. Most recently, polyurethane grafts have been 
proven to be more effective then the alternative materials, 
though they may be carcinogenic.  
 In 1995, about 50% of vein grafts failed within 10 years 
due to neointimal hyperplasia, or the closing of the vein from 
the inside by the buildup of plaque, cholesterol, and other 
particles found in the blood[1]. When this happens, smooth 
muscle cells (SMC) line the inside of the graft in response to 
stress from the surgery or shear stress from blood flow. These 
cells quickly buildup and are extremely prone to 
atherosclerosis. When this happens, a temporary fix is balloon 
angioplasty, in which a catheter is inserted to the site of 
Materials/Methods Discussion/Conclusion 
Based on my research so far, the tentative answer to my 
research question is that everolimus coatings linked to 
polytetrafluoroethylene (PTFE) grafts by poly(n-butyl 
methacrylate) (PBMA) should be subjected to further clinical 
research and in-vivo trials. I think the authors who advocate for 
PTFE grafts have stronger studies with more conclusive 
evidence, especially compared to those who like resorbable 
models. The main point of contention exists in the type of drug 
that could be added to make a composite graft, as well as the 
nature of the polymer that would anchor it. I think most 
scientists realize that the future of grafts lies in bio-absorbable 
polymers, but more improvements need to be made in the mean 
time since current models are not completely safe and elude too 
quickly. As of right now, cobalt and chromium PTFE grafts are 
the most successful in people without risk of heart attack, 
everolimus is the best drug, and PBMA is the most effective 
polymer.  
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Results 
of blockage, and then a balloon expands to widen the vein and push the plaque to 
the outside of the vein. A filter basket is placed downstream from the balloon to 
catch any debris that may have been knocked loose. In cases of more severe 
atherosclerosis, however, this is not possible.  
 Ideally, engineered endothelial cells could be added to the graft, but that would 
require overcoming several technological and biological barriers: finding the 
problem genes, inserting the replacement genes into the endothelial cells without 
stimulating an immune response, culturing those cells, and attaching the cells to the 
grafts. Instead, engineering the exterior and then adding a coating would be much 
easier. According to the Duke Department of Vascular Surgery, the ideal graft 
would allow a flow rate of 500 mL/min, resist infection, not cause an immune 
system response, and be inserted easily. Furthermore, the graft access should not 
have weeping, be easily clipped, resist infection, and be revised if need be [2]. 
To better comprehend the clinical standards and developing alternatives, I collected 
previously identified physical and chemical venous properties, as well as the 
corresponding synthetic materials that would support them. I compiled studies of 
primary and secondary endpoints (such as death, myocardial infarction, thrombosis, 
and target-lesion revascularization) in various graft materials, polymer coatings, and 
drugs to gauge efficacy.  
In comparisons between various vein graft exteriors, polymers, and drugs, 
polytetrafluoroethylene (PTFE) grafts lasted the longest, everolimus was the drug 
that decreased primary endpoint failure the most, and poly(n-butyl methacrylate) 
(PBMA) acted as the most efficient interface. The only caveats in this combination 
is that PTFE is still being investigated as a carcinogen, and that everolimus may 
increase the risk of myocardial infarction, or heart attack. The next best alternative 
is sirolimus, which has been widely used since the early 2000s and is anchored by 
poly(n-butyl methacrylate) (PBMA)  and poly(ethylene-co-vinyl acetate) (PEVA). 
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